- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04361227
Utility of OverStitch Sx After ESD
Prospective Study of Utility of OverStitch Sx Endoscopic Suturing System After ESD Procedure
Study Overview
Status
Conditions
Detailed Description
Resection of gastrointestinal neoplastic lesions at an early stage has been associated with improved clinical outcomes. While surgery has been traditionally performed for the resection of these precancerous or cancerous lesions confined to the mucosa of the GI tract, it is often associated with a higher morbidity and mortality rate compared to alternative endoscopic therapies. Recently, endoscopic submucosal dissection (ESD) has emerged as a new endoscopic technique that allows en-bloc resection of GI lesions, irrespective of size. In comparison to other endoscopic techniques, such as endoscopic mucosal resection (EMR), ESD is associated with higher curative resection rates and lower recurrence. While ESD was initially developed for the treatment of gastric cancer in Asia, which is relatively rare in the West, this technique would intuitively seem suitable for the resection of other superficial neoplastic lesions in the GI tract (i.e. large colon polyps, Barrett's mucosa, early non-invasive cancer). With the differences in patient population and disease location one can anticipate some differences in outcomes between ESD performed in Asian and US patients. Endoscopic Submucosal Dissection (ESD) is considered the gold standard for removal of pre-cancerous lesions from the GI tract, as histological analysis is more definitive, and the recurrence rate is lower as compared to endoscopic mucosal resection (EMR).
While ESD is useful for therapeutic and diagnostic purposes, the technique is rather difficult and detailed requiring extended procedure times. The most common complications of the ESD techniques are bleeding and perforation. Other rare complications include aspiration pneumonia, air embolisms, or stenosis. For this reason, closure of the mucosa following an endoscopic resection became an area of increased interest.
A randomized study in October of 2019 examined if prophylactic closure of a mucosal defect with clips would reduce the risk of bleeding following endoscopic intervention by EMR. 919 patients were randomly assigned to groups with 3.5% of patients experiencing post-procedure bleeding compared to 7.1% within the control group. Through this randomized trial, they found a significant reduction in post-procedural bleeding when patients undergo endoscopic clip closure of the mucosal defect.
With the advancements in endoscopic therapy, post-procedural clipping is now a well-established means of treatment following mucosal resections. Clipping, however, has two limitations including their inability to close large defects and the increasing difficulty in removal of those clips. To address these issues, endoscopic suturing systems have been developed which simulate the effectiveness of surgical stitching. The OverStitch Sx (Apollo Endosurgery Inc.) is commercially available and widely used in various applications such as the fixation of esophageal stents, suturing of ulcers, or reduction of anastamoses in bariatric surgeries.
Kantsevoy et al. in a 2014 retrospective study has shown that large mucosal defects treated with endoscopic suturing following an ESD resulted in a decrease rate of adverse events as well as the need for hospitalizations. All patient lesions were successfully and completely closed with no delayed or immediate adverse events following the procedure. The study concludes that the use of the Overstitch Sx device is fast and feasible and can decrease treatment costs by reducing the need to hospitalize patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults age 18-99, who are scheduled to undergo ESD procedure with possible mucosal defect closure.
Exclusion Criteria:
- Age is less than 18 years old
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical/technical success rate utilizing endosuture
Time Frame: 2 years
|
To assess feasibility and technical success of using Overstitch Sx system for closure after ESD
|
2 years
|
Rate of patients reported with bleeding/perforation post-ESD procedure
Time Frame: 2 years
|
Conduct follow-ups for risk of bleeding and perforation after closure
|
2 years
|
Closure time after ESD
Time Frame: 2 years
|
Record time needed to close lesion
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional clip closure
Time Frame: 2 years
|
Identify, if any, need for additional clipping after endoscopic suture closure
|
2 years
|
Clips used post-ESD
Time Frame: 2 years
|
Record number of sutures needed to close lesion
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-47184
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Brigette MaRecruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Henan Cancer HospitalUnknownAdvanced Gastrointestinal TumorsChina